Octagon Capital Advisors’s Abivax ABVX Stock Holding History

Octagon Capital Advisors’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$132M	Buy	993,000 +316,000	+47%	+$35.8M	11.89%	3
2026 Q1	$75.4M	Sell	677,000 -79,000	-10%	-$9.35M	8.34%	3
2025 Q4	$102M	Sell	756,000 -569,000	-43%	-$62.1M	12.38%	1
2025 Q3	$112M	Buy	1,325,000 +58,000	+5%	+$3.56M	17.05%	1
2025 Q2	$9.69M	Buy	1,267,000 +37,000	+3%	+$241K	2.13%	20
2025 Q1	$7.69M	Buy	+1,230,000	New	+$8.32M	1.49%	26

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Jupiter Topco New York $245B AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Octagon Capital Advisors's ABVX Position: Q2 2026 in Review

Octagon Capital Advisors increased its Abivax (ABVX) stake by 47% in Q2 2026, buying an estimated $35.8M and bringing the position to 993,000 shares worth $132M. The position accounts for 11.89% of the portfolio, ranked #3.

Octagon Capital Advisors first reported a position in ABVX in Q1 2025 and has held it in 6 quarters since. 303 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

Octagon Capital Advisors held 993,000 shares of Abivax worth $132M as of Q2 2026.
Octagon Capital Advisors bought 316,000 Abivax shares in Q2 2026, an estimated $35.8M.
Abivax made up 11.89% of Octagon Capital Advisors's portfolio in Q2 2026, its #3 holding.
Octagon Capital Advisors first reported a position in Abivax in Q1 2025 and has held it in 6 quarters since.
303 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Octagon Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.